Abstract
Fluvastatin sodium (Lescol, Novartis Pharmaceutical Corp., East Hanover, NJ, U.S.A.), a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG Co-A) reductase inhibitor that limits cholesterol biosynthesis, is available as a 40-mg immediate-release formulation capsule. An extended-release formulation for once-daily administration has been developed for patients with primary hypercholesterolemia who may benefit from doses higher than 40 mg/day. This phase I study evaluated the safety, tolerability, and pharmacokinetics of a new fluvastatin extended-release formulation at doses ranging from 80-640 mg/day in 40 hypercholesterolemic patients. After a 2-week dietary stabilization phase, patients (Fredrickson type IIa/IIb), 18-55 years of age, were randomly assigned to four groups to receive oral fluvastatin extended-release (80, 160, 320, or 640 mg) or matching placebo once daily for 13 days. Fluvastatin extended-release was generally safe and well tolerated at doses of 80-320 mg/day. Within this dose range, linear pharmacokinetics was observed after single and multiple dosing. At 640 mg, fluvastatin extended-release was not well tolerated. Six of the seven actively treated patients at this dose experienced adverse events, including diar...Continue Reading
References
Jul 1, 1992·Journal of Clinical Pharmacology·F L TseA Troendle
Nov 16, 1995·The New England Journal of Medicine·J ShepherdC J Packard
May 26, 1994·The American Journal of Cardiology·L A Jokubaitis
Nov 1, 1993·American Journal of Hypertension·H T SmithW T Robinson
May 5, 1993·Journal of Chromatography·G KalafskyM G Choc
Jan 1, 1996·Drugs·R G Finch
Oct 3, 1996·The New England Journal of Medicine·F M SacksE Braunwald
Aug 1, 1997·The American Journal of Cardiology·J A HerdA M Gotto
Jun 5, 1998·JAMA : the Journal of the American Medical Association·J R DownsA M Gotto
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Mar 13, 1999·European Heart Journal·P W SerruysP J Pfister
May 11, 1999·Drugs·H D Langtry, A Markham
Jun 25, 1999·Atherosclerosis·G RieggerD Welzel
Oct 6, 2000·The American Journal of Cardiology·C M BallantyneB S Trippe
Feb 24, 2001·Clinical Therapeutics·A G OlssonUNKNOWN Fluvastatin Study Group
Citations
Jan 25, 2013·Clinical Pharmacokinetics·Anne-Charlotte CastellanUNKNOWN Genophar Working Group
Feb 22, 2002·Current Opinion in Nephrology and Hypertension·Domenic A Sica, Todd W B Gehr
Jan 5, 2002·The American Journal of Geriatric Cardiology·Domenic A Sica, Todd W B Gehr
Feb 28, 2002·Journal of Clinical Pharmacology·S Appel-DingemanseM Merz
Jun 18, 2004·Drugs·Alberto CorsiniChristie M Ballantyne
Sep 11, 2008·Pharmacogenomics·Philippe CouvertAlain Carrié
Apr 11, 2001·Clinical Therapeutics·C M BallantyneY T Chiang
Jun 19, 2010·Expert Opinion on Drug Safety·Michiel T VoûteDon Poldermans
May 24, 2007·Current Medical Research and Opinion·B IlerigelenUNKNOWN TULIPS Investigators
Mar 18, 2008·Clinical Therapeutics·Luis A Alvarez-SalaXavier Pintó
Dec 14, 2004·International Journal of Clinical Practice·G De Angelis
Sep 9, 2008·Journal of Cardiovascular Electrophysiology·Yu-Feng HuShih-Ann Chen
Apr 2, 2005·Current Medical Research and Opinion·Evagelos N LiberopoulosMoses S Elisaf
Sep 8, 2005·Expert Opinion on Pharmacotherapy·Mark Y Chan, Chi Hang Lee
Nov 20, 2002·Expert Opinion on Pharmacotherapy·J M Lawrence, J P D Reckless
Nov 2, 2013·Neuromuscular Disorders : NMD·M Needham, F L Mastaglia
Sep 8, 2004·Expert Review of Cardiovascular Therapy·Anders Asberg, Hallvard Holdaas
Apr 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Paul Scuffham
Feb 7, 2002·Pharmacoepidemiology and Drug Safety
Oct 31, 2006·Pharmacoepidemiology and Drug Safety·David L McClureJohn E Hokanson
Apr 16, 2008·The American Journal of Gastroenterology·Ted BaderMuhammad Hasan
Mar 17, 2006·Rapid Communications in Mass Spectrometry : RCM·Ramakrishna V S NirogiPraveen V Datla
Nov 21, 2002·Current Opinion in Lipidology·Chiara BolegoRodolfo Paoletti
Jul 16, 2020·Leukemia·Joseph LongoLinda Z Penn
Aug 3, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Andras Vermes, Istvan Vermes
Apr 3, 2008·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Steven K Baker, Imtiaz A Samjoo
Feb 20, 2021·Cancer Research·Rosemary YuLinda Z Penn
Jul 20, 2005·Molecular Pharmaceutics·Anders LindahlHans Lennernäs